Get the Stockscreener App
6.00
5.08%
0.29
After Hours:
6.11
0.11
+1.83%
Aldeyra Therapeutics Inc stock is traded at $6.00, with a volume of 596.55K.
It is up +5.08% in the last 24 hours and up +13.85% over the past month.
Aldeyra Therapeutics Inc is a biotechnology company engaged in developing and commercializing next-generation medicines to improve the lives of patients with immune-mediated diseases. The company's product candidate, reproxalap, is a first-in-class treatment in late-stage development for dry eye disease and allergic conjunctivitis. In addition, it also has additional product candidates in development for proliferative vitreoretinopathy, primary vitreoretinal lymphoma and other retinal diseases, autoimmune disease, and cancer.
See More
Previous Close:
$5.71
Open:
$5.73
24h Volume:
596.55K
Relative Volume:
1.37
Market Cap:
$357.30M
Revenue:
-
Net Income/Loss:
$-44.80M
P/E Ratio:
-8.00
EPS:
-0.75
Net Cash Flow:
$-30.67M
1W Performance:
+11.11%
1M Performance:
+13.85%
6M Performance:
+74.42%
1Y Performance:
+79.64%
1-Day Range:
$5.71
$6.15
1-Week Range:
$5.0279
$6.15
52-Week Range:
$2.71
$6.5476
Aldeyra Therapeutics Inc Stock (ALDX) Company Profile
Name
Aldeyra Therapeutics Inc
Sector
Industry
Phone
781-761-4904
Address
131 HARTWELL AVENUE, LEXINGTON, MA
Compare ALDX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ALDX
Aldeyra Therapeutics Inc
|
6.00 | 357.30M | 0 | -44.80M | -30.67M | -0.75 |
|
VRTX
Vertex Pharmaceuticals Inc
|
481.16 | 123.91B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
722.07 | 78.94B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
657.97 | 39.98B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
278.25 | 35.89B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
119.94 | 28.75B | 3.30B | -501.07M | 1.03B | -2.1146 |
Aldeyra Therapeutics Inc Stock (ALDX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-03-24 | Upgrade | Oppenheimer | Perform → Outperform |
| Apr-02-24 | Resumed | H.C. Wainwright | Buy |
| Apr-27-22 | Resumed | H.C. Wainwright | Buy |
| Feb-08-21 | Initiated | H.C. Wainwright | Buy |
| Dec-16-20 | Initiated | Berenberg | Buy |
| Oct-30-20 | Initiated | Jefferies | Buy |
| Oct-16-20 | Initiated | BTIG Research | Buy |
| Sep-22-20 | Initiated | Alliance Global Partners | Buy |
| May-12-20 | Initiated | Oppenheimer | Outperform |
| Dec-04-18 | Initiated | Citigroup | Buy |
| Sep-26-18 | Reiterated | Cantor Fitzgerald | Overweight |
| Sep-13-18 | Initiated | Janney | Buy |
| Jan-26-18 | Initiated | Seaport Global Securities | Buy |
| Sep-26-16 | Initiated | H.C. Wainwright | Buy |
| Jul-01-16 | Initiated | Stifel | Buy |
| Jul-01-15 | Initiated | Canaccord Genuity | Buy |
| Mar-25-15 | Initiated | Chardan Capital Markets | Buy |
| Mar-20-15 | Reiterated | H.C. Wainwright | Buy |
| Nov-18-14 | Initiated | H.C. Wainwright | Buy |
| Jun-19-14 | Initiated | Aegis Capital | Buy |
View All
Aldeyra Therapeutics Inc Stock (ALDX) Latest News
Aldeyra Therapeutics (NASDAQ:ALDX) Has Debt But No Earnings; Should You Worry? - Simply Wall St
Short Interest in Aldeyra Therapeutics, Inc (NASDAQ:ALDX) Grows By 8.2% - MarketBeat
Exclusive Fireside Chat: Aldeyra CEO Reveals Company Strategy at Major Healthcare Conference - StockTitan
Aldeyra Therapeutics (NASDAQ:ALDX) Shares Pass Below 200-Day Moving AverageHere's What Happened - MarketBeat
Dry Eye Disease Market to Observe Stupendous Growth by 2034 | DelveInsight - The Malaysian Reserve
Aldeyra Therapeutics (NASDAQ:ALDX) Stock Price Crosses Below 200-Day Moving Average – Here’s Why - Defense World
ALDX (Aldeyra Therapeutics) Cash-to-Debt : 7.22 (As of Sep. 2024) - GuruFocus.com
Aldeyra Therapeutics, Inc (NASDAQ:ALDX) Short Interest Up 8.2% in December - Defense World
Is Aldeyra Therapeutics (ALDX) Among Billionaire Joseph Edelman’s Long-Term Stock Picks? - Insider Monkey
Billionaire Joseph Edelman’s Top 10 Long-Term Stock Picks - Insider Monkey
Barclays PLC Acquires 48,313 Shares of Aldeyra Therapeutics, Inc (NASDAQ:ALDX) - Defense World
Jane Street Group LLC Has $128,000 Stock Position in Aldeyra Therapeutics, Inc (NASDAQ:ALDX) - Defense World
International Assets Investment Management LLC Has $312,000 Stock Position in Aldeyra Therapeutics, Inc (NASDAQ:ALDX) - MarketBeat
Aldeyra Therapeutics, Inc (NASDAQ:ALDX) Shares Bought by Barclays PLC - Defense World
Geode Capital Management LLC Has $6.01 Million Holdings in Aldeyra Therapeutics, Inc (NASDAQ:ALDX) - Defense World
3 US Penny Stocks With Market Caps Over $80M To Watch - Simply Wall St
State Street Corp Purchases 16,188 Shares of Aldeyra Therapeutics, Inc (NASDAQ:ALDX) - Defense World
Aldeyra Therapeutics (NASDAQ:ALDX) Stock Crosses Below 50 Day Moving AverageTime to Sell? - MarketBeat
Aldeyra, UnitedHealth Group Incorporated, Blue Ridge Bankshares, and Amplitude Investigation - The Bakersfield Californian
Aldeyra, UnitedHealth Group Incorporated, Blue Ridge - GlobeNewswire
Aldeyra Therapeutics: Key Inflection Point Ahead (NASDAQ:ALDX) - Seeking Alpha
4 Stock-ing Stuffers for Under $10 a Share - TheStreet
High Growth Tech Stocks To Watch In December 2024 - Simply Wall St
BNP Paribas Financial Markets Acquires 10,201 Shares of Aldeyra Therapeutics, Inc (NASDAQ:ALDX) - Defense World
Aldeyra Therapeutics, Inc (NASDAQ:ALDX) Shares Sold by Verition Fund Management LLC - MarketBeat
Is the Options Market Predicting a Spike in Aldeyra Therapeutics (ALDX) Stock? - MSN
Aldeyra stock retains Outperform rating on strong DED drug outlook By Investing.com - Investing.com Australia
Aldeyra stock retains Outperform rating on strong DED drug outlook - Investing.com
Aldeyra Therapeutics, Inc (NASDAQ:ALDX) Short Interest Down 12.3% in November - Defense World
Short Interest in Aldeyra Therapeutics, Inc (NASDAQ:ALDX) Drops By 12.3% - MarketBeat
Objective long/short (ALDX) Report - Stock Traders Daily
Aldeyra Therapeutics, Inc (NASDAQ:ALDX) Shares Purchased by Jacobs Levy Equity Management Inc. - MarketBeat
Aldeyra Therapeutics, Inc (NASDAQ:ALDX) Sees Large Increase in Short Interest - MarketBeat
Aldeyra Therapeutics CEO to Present at Citi Healthcare Conference Ophthalmology Panel - StockTitan
Final Deadline Alert: ALDX Investor Alert: Contact Bronstein, Ge - GuruFocus.com
Eagle Asset Management Inc. Lowers Stock Position in Aldeyra Therapeutics, Inc (NASDAQ:ALDX) - MarketBeat
ALDX Up as FDA Accepts Resubmitted NDA for Eye Drug Reproxalap - MSN
Aldeyra announces FDA acceptance of resubmitted reproxalap application - MSN
Top US Penny Stocks To Watch In November 2024 - Simply Wall St
Perceptive Advisors buys 200,000 shares of Aldeyra Therapeutics Inc's common stock on Sept 19 - Reuters.com
Aldeyra Therapeutics Inc Stock (ALDX) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.82%
0.53%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):